Coronado Biosciences (NASDAQ: CNDO) is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are:
1. TSO (Trichuris suis ova or CNDO-201) a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and
2. CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.
The Company is scheduled to initiate a Phase II double-blind, placebo controlled trial of TSO for the treatment of Crohn's Disease in 2Q 2012 and a Phase I/II allogeneic clinical trial of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML) planned for 2Q 2012. Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs.
The Company announced that Dr. Bobby W. Sandage, Jr., Coronado's President and CEO, will present at the at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012, at 12:00 PM ET. The conference will be held at the Waldorf Astoria Hotel in New York City.
For more information please see www.CoronadoBiosciences.com.